In August 2016, Janssen Research & Development—a Janssen Pharmaceutical Company of Johnson & Johnson—announced that an isomer of ketamine, called esketamine, had received Breakthrough Therapy Designation by the Food & Drug Administration (FDA). Similarly to ketamine, esketamine has shown huge promise as a depression treatment, especially for those experiencing suicidal ideation, or who have resisted other treatment methodologies.
It’s a frustrating situation, to have this miraculous drug – a drug that is capable of changing and saving lives – so readily available, and yet so inaccessible. Without FDA approval, the overwhelming majority of insurance companies will not cover the cost of ketamine infusion therapy, leaving millions of Americans to suffer in the despair of severe depression. Private label ketamine clinics are operating around the country, but average prices of $500-800 per infusion are inhibitive at best. Even at our clinic, offering the lowest-priced ketamine infusions in the country, this potentially life-changing treatment is still not an option for many people.